Literature DB >> 32592816

Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent.

Osama El Shamy1, Joseph A Vassalotti2, Shuchita Sharma2, Teresa Aydillo-Gomez3, Nada Marjanovic4, Irene Ramos4, Adolfo García-Sastre5, Jaime Uribarri2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32592816      PMCID: PMC7313488          DOI: 10.1016/j.kint.2020.06.012

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


× No keyword cloud information.
To the editor: Acute peritoneal dialysis (PD) has been used in coronavirus disease 2019 (COVID-19) as an alternative to intermittent hemodialysis or continuous renal replacement therapy to mitigate the overwhelming demand for dialysis. , Liters of PD effluent are discarded in the sewerage system on a daily basis by both patients and medical institutions performing PD. Detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the peritoneal waste of a COVID-19 infected patient with end-stage kidney disease was previously reported. Given the uncertainty regarding the risk for viral transmission through the handling of PD effluent of patients with confirmed COVID-19 infections, we set out to determine the presence and infectivity of the SARS-CoV-2 virus in the PD effluent of 10 admitted patients with severe COVID-19 pneumonia (Table 1 ) treated with acute PD.
Table 1

Patient demographics, characteristics, and serum levels of selected markers of renal function and inflammation

CharacteristicsResult
Age (yr)60 ± 9
Weight (kg)98.9 ± 25
Body mass index (kg/m2)34.5 ± 8.8
Race (%)
 African American70
 White10
Ethnicity: Hispanic (%)20

IQR, interquartile range.

Patient demographics, characteristics, and serum levels of selected markers of renal function and inflammation IQR, interquartile range. Despite rigorous testing, we could not detect presence of the SARS-CoV-2 virus in the PD effluent. Using control samples, the limit of detection of the quantitative reverse transcription polymerase chain reaction was 1–5 copies of RNA or infectious viral particles per reaction. This test is as sensitive as the accepted US Food and Drug Administration–approved panel (limit of detection: 5 copies/reaction of quantified RNA transcripts). We also determined an absence of infective particles with no cytopathogenic effects seen after a week of monitoring of cell cultures in cell fractions and supernatants recovered from PD effluent, and a lack of plaque formation. Our study demonstrates that the risk of transmission of the virus through PD effluent is low, with an absence of infective viral particles and undetectable viral RNA. These are significant findings for potential future COVID-19 outbreaks and infection control.
  7 in total

Review 1.  The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.

Authors:  Qin Ning; Di Wu; Xiaojing Wang; Dong Xi; Tao Chen; Guang Chen; Hongwu Wang; Huiling Lu; Ming Wang; Lin Zhu; Junjian Hu; Tingting Liu; Ke Ma; Meifang Han; Xiaoping Luo
Journal:  Signal Transduct Target Ther       Date:  2022-02-23

2.  SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19.

Authors:  Xiaoling Wang; Amrish Patel; Lela Tisdale; Zahin Haq; Xiaoling Ye; Rachel Lasky; Priscila Preciado; Xia Tao; Gabriela Ferreira Dias; Joshua E Chao; Mohamad Hakim; Maggie Han; Ohnmar Thwin; Jochen Raimann; Dinesh Chatoth; Peter Kotanko; Nadja Grobe
Journal:  Kidney360       Date:  2020-12-01

3.  Presence of SARS-CoV-2 Antibodies in Spent Peritoneal Dialysate.

Authors:  Xiaoling Wang; Nadja Grobe; Amrish Patel; Shuchita Sharma; Jaime Uribarri; Peter Kotanko
Journal:  J Am Soc Nephrol       Date:  2021-07-06       Impact factor: 14.978

4.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in peritoneal fluid of coronavirus disease 2019 (COVID-19) patients-Prevalence and significance.

Authors:  Barbara Seeliger; Patrick Pessaux
Journal:  Surgery       Date:  2021-02-16       Impact factor: 3.982

Review 5.  COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.

Authors:  Khalil El Karoui; An S De Vriese
Journal:  Kidney Int       Date:  2022-02-14       Impact factor: 18.998

6.  Positive peritoneal swab in SARS-CoV-2 patients undergoing abdominal emergency surgery: effect or cause?

Authors:  Dario Tartaglia; Andrea Barberis; Federico Coccolini; Mauro Pistello; Mariangela Rutigliani; Massimo Chiarugi
Journal:  Infection       Date:  2022-03-02       Impact factor: 7.455

7.  Absence of SARS-CoV-2 RNA in Peritoneal Fluid During Surgery in Pregnant Women Who Are COVID-19 Positive.

Authors:  Artur J Jakimiuk; Marcin Januszewski; Malgorzata Santor-Zaczynska; Alicja A Jakimiuk; Tomasz Oleksik; Marek Pokulniewicz; Waldemar Wierzba
Journal:  J Minim Invasive Gynecol       Date:  2021-06-15       Impact factor: 4.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.